Pregnancy, Fetal, and Infant Outcomes Following Maternal Exposure to Glatiramer Acetate During Pregnancy and Breastfeeding.

Published in: Drug safety (2022)

Maternal exposure to glatiramer acetate does not appear to be related to adverse pregnancy, fetal, or infant outcomes. These data further support the safety of both glatiramer acetate 20-mg/mL and 40-mg/mL treatments during pregnancy and breastfeeding.

Keyphrases

pregnancy outcomes
preterm infants
preterm birth
birth weight
pregnant women
electronic health record
emergency department
body mass index
physical activity
weight gain
adipose tissue
deep learning
insulin resistance
skeletal muscle